Developer docs
API playgroundTry for free, no card

Search company profiles

Biomere

Full company profile

uuid000drvo

Namestring
Biomere
Legal namestring
Biomere
Websiteurl
biomere.com
Company typeenum
Private
Founded yearint
1996
Descriptiontext

Biomere is a US-based preclinical contract research organization (CRO) founded in 1996 as a spin-out from the University of Massachusetts Medical School and headquartered in Worcester, Massachusetts. The company specializes in non-GLP pharmacokinetic/pharmacodynamic (PK/PD) studies and early toxicology using in vivo small and large animal models, including rodents, rabbits, and non-human primates. It operates a 100,000 sq ft AAALAC-accredited, OLAW-assured, DEA-licensed, and USDA-registered facility described as the largest NHP laboratory in New England, and runs roughly 350 rodent and 100 large animal studies per year with a stated >95% client retention rate.

Its service portfolio spans eight integrated lines: gene therapy PK/PD (AAV, LNP, oligonucleotide, mRNA, siRNA, CRISPR), ocular disease models and dosing, general PK/PD characterization, colony management for genetically modified mice, laboratory sciences (flow cytometry, multiplex MSD, qPCR, clinical chemistry, LC-MS), surgical services (CSF catheterization, ICM/ICV dosing, specialty biopsies), disease models across metabolic, oncology, autoimmune, and CNS areas, and therapeutic-area dosing expertise. Biomere maintains a multi-channel commercial motion combining enterprise field sales, marketplace storefronts on Scientist.com and ScienceExchange, scientific content marketing (The Exchange podcast, webinars, posters at SOT/ARVO/ASGCT/ACT), and a private life-science community called The Concourse. Partnerships with SauveBio (flow cytometry), Splice Histology (histology), and Emulate Inc. (Organ-Chip) extend the offering toward an integrated, single-vendor preclinical data package.

Biomere was acquired by JOINN Laboratories, the largest public nonclinical CRO in China, in 2019, and now operates as a wholly-owned subsidiary within JOINN's global network of facilities in the US (Worcester, Richmond CA) and China (Suzhou, Beijing, Wuzhou, Chongqing, Guangzhou). The economic model is fee-for-service professional services revenue with custom quote-based pricing and multi-year engagements; revenue is not publicly disclosed. A planned 2026 launch of Organ-Chip services via Emulate represents a deliberate extension of the platform beyond traditional in vivo work.

Short descriptiontext

Biomere is a US preclinical CRO (Worcester, MA) acquired by China's JOINN Laboratories in 2019, providing non-GLP PK/PD and early toxicology in vivo studies in rodents and NHPs to pharma, biotech, and academic clients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersWorcester, United States
HQ citystring
Worcester
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical CRO services, pharmacokinetic studies, early toxicology testing, non-human primate research, animal model services
Industry3 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Contract Research Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Preclinical Contract Research Services
TypeProfessional Services
Description

Biomere generates revenue through fee-for-service preclinical contract research engagements. Clients engage Biomere to conduct non-GLP PK/PD studies, early toxicology studies, and related endpoint analysis across small and large animal models. Pricing is project-based and quote-driven, varying by study complexity, species, number of endpoints, and duration.

biomere.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
Pricing details1 tier
1Custom study-based pricing for preclinical PK/PD and early toxicology contract research services
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed. Projects are scoped individually based on client requirements including species, study design, endpoints, and timeline.

biomere.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Biomere is a Boston-area preclinical contract research organization (CRO) that delivers non-GLP pharmacokinetic/pharmacodynamic (PK/PD) and early toxicology studies in rodent, large animal, and non-human primate models. The company operates extensive AAALAC-accredited vivarium space and integrated laboratory sciences (flow cytometry, MSD multiplex assays, qPCR, clinical chemistry) to generate endpoint data packages that support go/no-go decisions and the transition from lead optimization to IND-enabling studies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • >95% client retention rate
+4 more records
Product overview1 text field

Biomere is a preclinical Contract Research Organization (CRO) offering a portfolio of integrated services rather than a single software product. The core service offering includes PK/PD Characterization, Gene Therapy PK/PD, Ocular Disease Models, Laboratory Sciences (endpoint analysis), Colony Management Solutions, Surgical Services, Disease Models, and Therapeutic Area Expertise. These services are designed to work together as an end-to-end preclinical drug development offering, where clients can run dosing, sample collection, and downstream endpoint analysis under a single CRO, supporting the transition from lead optimization to IND-enabling studies.

Product and service9 records
1Gene Therapy PK/PD
CategoryPreclinical Gene Therapy Services
2Ocular Disease Models and PK/PD
CategoryPreclinical Ocular Services
3PK/PD Characterization Services
CategoryPreclinical PK/PD Services
4Laboratory Sciences
CategoryEndpoint Analysis Services
5Colony Management Solutions
CategoryAnimal Colony Services
6Surgical Services
CategoryPreclinical Surgical Services
7Disease Models
CategoryPreclinical Disease Models
8Therapeutic Area Expertise
CategoryTherapeutic Area Services
9Organ-Chip Services
CategoryIn Vitro / Organ-Chip Services
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1JOINN Laboratories (Parent Company)
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

JOINN Laboratories, the largest public nonclinical CRO in China, acquired Biomere in 2019. This acquisition created a globally integrated drug development CRO service offering. Biomere's non-GLP PK/PD and early toxicology services complement JOINN's full GLP toxicology and clinical trial support capabilities, enabling seamless program progression from discovery through IND-enabling studies. JOINN has facilities in Suzhou, Beijing, Wuzhou, Chongqing, and Guangzhou in China, and Richmond CA in the US.

biomere.com
Strategic tierCoreTypeTechnology or Integration
Description

Biomere and SauveBio announced a partnership combining Biomere's in vivo PK/PD and early toxicology expertise with SauveBio's flow cytometry and cell sorting capabilities. This collaboration delivers comprehensive data packages to support program needs and help clients make critical go/no-go decisions. SauveBio provides high-fidelity cell sorting for applications including rare immune subset isolation, single-cell RNA sequencing quality control, and GFP+ cell sorting for gene therapy vector validation.

Strategic tierCoreTypeTechnology or Integration
Description

Biomere partnered with Splice Histology to combine Biomere's in vivo PK/PD and early toxicology expertise with Splice Histology's full-service histology services. Splice Histology is a veteran and locally owned company supporting hospitals and biotechs with pre-diagnostic and preclinical workflow histology services. The partnership results in complete preclinical data packages for go/no-go decisions.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Emulate develops Organ-Chip (microphysiological) technology for preclinical testing, including Liver-Chip and Kidney-Chip applications. It is comparable to Biomere as a partner and partial substitute, providing an in vitro alternative to certain in vivo preclinical studies.

TypeDirect peer
Description

Inotiv is a US-focused preclinical CRO and research models provider offering in vivo safety assessment, PK/PD, and toxicology services. It is one of the closest direct competitors to Biomere in the mid-sized US preclinical CRO segment, particularly for rodent and NHP work.

TypeBroad incumbent
Description

Eurofins operates a global network of laboratory testing and contract research services including preclinical and bioanalytical offerings. It is a broad incumbent comparable to Biomere in the bioanalytical and laboratory sciences portion of the workflow.

4JOINN Laboratories
TypeDirect peer
Description

JOINN is Biomere's parent and the largest nonclinical CRO in China, offering GLP toxicology and clinical support. It is the most directly comparable peer, with overlapping service lines and a footprint (China plus Richmond, CA) that overlaps Biomere's offering.

TypeBroad incumbent
Description

WuXi AppTec is a global CRO/CDMO with preclinical, bioanalytical, and biologics capabilities including in vivo PK/PD and toxicology. It competes with Biomere for US and global preclinical engagements and is a key comparable for nonclinical service scale and breadth.

TypeBroad incumbent
Description

Charles River is the largest preclinical CRO globally with extensive in vivo PK/PD, toxicology, and research models services spanning rodents and NHPs. It directly competes with Biomere for preclinical PK/PD and safety assessment work and is the benchmark incumbent in the same category.

TypeDirect peer
Description

Pharmaron is a China-origin CRO/CDMO with integrated preclinical drug discovery and in vivo PK/PD, bioanalysis, and safety assessment services. It is comparable to Biomere in its preclinical CRO positioning and global service mix, particularly for US and Asia-based sponsors.

TypeDirect peer
Description

Frontage is a US-headquartered CRO providing preclinical and bioanalytical services including in vivo PK/PD, toxicology, and bioanalysis. It is comparable to Biomere in service mix and customer base among small and mid-cap biopharma sponsors.

TypeRegional player
Description

Medicilon is a China-based preclinical CRO offering in vivo PK/PD, toxicology, and bioanalytical services with a US presence. It is comparable to Biomere in preclinical service scope, particularly for sponsors seeking China-based execution and IND-enabling support.

TypeBroad incumbent
Description

Labcorp's Covance segment operates a global preclinical and clinical CRO with full GLP toxicology, PK/PD, and bioanalytical capabilities. It competes with Biomere across early-stage in vivo studies and offers the larger, integrated alternative that sponsors often consolidate toward.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance10 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biomere

Preclinical Contract Research Servicesbiomere.com

Biomere is a US preclinical CRO (Worcester, MA) acquired by China's JOINN Laboratories in 2019, providing non-GLP PK/PD and early toxicology in vivo studies in rodents and NHPs to pharma, biotech, and academic clients.

What Biomere does

Biomere is a US-based preclinical contract research organization (CRO) founded in 1996 as a spin-out from the University of Massachusetts Medical School and headquartered in Worcester, Massachusetts. The company specializes in non-GLP pharmacokinetic/pharmacodynamic (PK/PD) studies and early toxicology using in vivo small and large animal models, including rodents, rabbits, and non-human primates. It operates a 100,000 sq ft AAALAC-accredited, OLAW-assured, DEA-licensed, and USDA-registered facility described as the largest NHP laboratory in New England, and runs roughly 350 rodent and 100 large animal studies per year with a stated >95% client retention rate.

Its service portfolio spans eight integrated lines: gene therapy PK/PD (AAV, LNP, oligonucleotide, mRNA, siRNA, CRISPR), ocular disease models and dosing, general PK/PD characterization, colony management for genetically modified mice, laboratory sciences (flow cytometry, multiplex MSD, qPCR, clinical chemistry, LC-MS), surgical services (CSF catheterization, ICM/ICV dosing, specialty biopsies), disease models across metabolic, oncology, autoimmune, and CNS areas, and therapeutic-area dosing expertise. Biomere maintains a multi-channel commercial motion combining enterprise field sales, marketplace storefronts on Scientist.com and ScienceExchange, scientific content marketing (The Exchange podcast, webinars, posters at SOT/ARVO/ASGCT/ACT), and a private life-science community called The Concourse. Partnerships with SauveBio (flow cytometry), Splice Histology (histology), and Emulate Inc. (Organ-Chip) extend the offering toward an integrated, single-vendor preclinical data package.

Biomere was acquired by JOINN Laboratories, the largest public nonclinical CRO in China, in 2019, and now operates as a wholly-owned subsidiary within JOINN's global network of facilities in the US (Worcester, Richmond CA) and China (Suzhou, Beijing, Wuzhou, Chongqing, Guangzhou). The economic model is fee-for-service professional services revenue with custom quote-based pricing and multi-year engagements; revenue is not publicly disclosed. A planned 2026 launch of Organ-Chip services via Emulate represents a deliberate extension of the platform beyond traditional in vivo work.

Biomere firmographics

Firmographics
Name
Biomere
Legal name
Biomere
Website
https://biomere.com
Company type
Private
Founded year
1996
Operating status
Operating
Headcount range
101–250 employees
Short description
Biomere is a US preclinical CRO (Worcester, MA) acquired by China's JOINN Laboratories in 2019, providing non-GLP PK/PD and early toxicology in vivo studies in rodents and NHPs to pharma, biotech, and academic clients.
Ownership category
akta.pro rank

Biomere industry classification

Industry
Product category
Preclinical Contract Research Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)

Keywords

  • Preclinical CRO services
  • Pharmacokinetic studies
  • Early toxicology testing
  • Non-human primate research
  • Animal model services

Where Biomere is headquartered

Location

Headquarters

HQ city
Worcester
HQ country
United States
HQ region
North America

Offices7 records

Markets served

Biomere business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Preclinical Contract Research Services: Biomere generates revenue through fee-for-service preclinical contract research engagements. Clients engage Biomere to conduct non-GLP PK/PD studies, early toxicology studies, and related endpoint analysis across small and large animal models. Pricing is project-based and quote-driven, varying by study complexity, species, number of endpoints, and duration.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom study-based pricing for preclinical PK/PD and early toxicology contract research services

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Biomere product offering

Product offering

Core offering

Biomere is a Boston-area preclinical contract research organization (CRO) that delivers non-GLP pharmacokinetic/pharmacodynamic (PK/PD) and early toxicology studies in rodent, large animal, and non-human primate models. The company operates extensive AAALAC-accredited vivarium space and integrated laboratory sciences (flow cytometry, MSD multiplex assays, qPCR, clinical chemistry) to generate endpoint data packages that support go/no-go decisions and the transition from lead optimization to IND-enabling studies.

Product overview

Biomere is a preclinical Contract Research Organization (CRO) offering a portfolio of integrated services rather than a single software product. The core service offering includes PK/PD Characterization, Gene Therapy PK/PD, Ocular Disease Models, Laboratory Sciences (endpoint analysis), Colony Management Solutions, Surgical Services, Disease Models, and Therapeutic Area Expertise. These services are designed to work together as an end-to-end preclinical drug development offering, where clients can run dosing, sample collection, and downstream endpoint analysis under a single CRO, supporting the transition from lead optimization to IND-enabling studies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Gene Therapy PK/PD
  • Ocular Disease Models and PK/PD
  • PK/PD Characterization Services
  • Laboratory Sciences
  • Colony Management Solutions
  • Surgical Services
  • Disease Models
  • Therapeutic Area Expertise
  • Organ-Chip Services

Quantifiable outcome

  • >95% client retention rate
  • +4 more outcomes

Companies that use Biomere

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Biomere technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Biomere partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship and core.

  • JOINN Laboratories (Parent Company)flagshipStrategic or Co-development Partner · 1 January 2019JOINN Laboratories, the largest public nonclinical CRO in China, acquired Biomere in 2019. This acquisition created a globally integrated drug development CRO service offering. Biomere's non-GLP PK/PD and early toxicology services complement JOINN's full GLP toxicology and clinical trial support capabilities, enabling seamless program progression from discovery through IND-enabling studies. JOINN has facilities in Suzhou, Beijing, Wuzhou, Chongqing, and Guangzhou in China, and Richmond CA in the US.
  • SauveBiocoreTechnology or IntegrationBiomere and SauveBio announced a partnership combining Biomere's in vivo PK/PD and early toxicology expertise with SauveBio's flow cytometry and cell sorting capabilities. This collaboration delivers comprehensive data packages to support program needs and help clients make critical go/no-go decisions. SauveBio provides high-fidelity cell sorting for applications including rare immune subset isolation, single-cell RNA sequencing quality control, and GFP+ cell sorting for gene therapy vector validation.
  • Splice HistologycoreTechnology or IntegrationBiomere partnered with Splice Histology to combine Biomere's in vivo PK/PD and early toxicology expertise with Splice Histology's full-service histology services. Splice Histology is a veteran and locally owned company supporting hospitals and biotechs with pre-diagnostic and preclinical workflow histology services. The partnership results in complete preclinical data packages for go/no-go decisions.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Biomere competitors and assessment

Company assessment

Emerging players

  • Emulate Inc. Emulate develops Organ-Chip (microphysiological) technology for preclinical testing, including Liver-Chip and Kidney-Chip applications. It is comparable to Biomere as a partner and partial substitute, providing an in vitro alternative to certain in vivo preclinical studies.

Direct peers

  • Inotiv: Inotiv is a US-focused preclinical CRO and research models provider offering in vivo safety assessment, PK/PD, and toxicology services. It is one of the closest direct competitors to Biomere in the mid-sized US preclinical CRO segment, particularly for rodent and NHP work.
  • JOINN Laboratories: JOINN is Biomere's parent and the largest nonclinical CRO in China, offering GLP toxicology and clinical support. It is the most directly comparable peer, with overlapping service lines and a footprint (China plus Richmond, CA) that overlaps Biomere's offering.
  • Pharmaron: Pharmaron is a China-origin CRO/CDMO with integrated preclinical drug discovery and in vivo PK/PD, bioanalysis, and safety assessment services. It is comparable to Biomere in its preclinical CRO positioning and global service mix, particularly for US and Asia-based sponsors.
  • Frontage Laboratories: Frontage is a US-headquartered CRO providing preclinical and bioanalytical services including in vivo PK/PD, toxicology, and bioanalysis. It is comparable to Biomere in service mix and customer base among small and mid-cap biopharma sponsors.

Broad incumbents

  • Eurofins Scientific: Eurofins operates a global network of laboratory testing and contract research services including preclinical and bioanalytical offerings. It is a broad incumbent comparable to Biomere in the bioanalytical and laboratory sciences portion of the workflow.
  • WuXi AppTec: WuXi AppTec is a global CRO/CDMO with preclinical, bioanalytical, and biologics capabilities including in vivo PK/PD and toxicology. It competes with Biomere for US and global preclinical engagements and is a key comparable for nonclinical service scale and breadth.
  • Charles River Laboratories: Charles River is the largest preclinical CRO globally with extensive in vivo PK/PD, toxicology, and research models services spanning rodents and NHPs. It directly competes with Biomere for preclinical PK/PD and safety assessment work and is the benchmark incumbent in the same category.
  • Labcorp (Covance): Labcorp's Covance segment operates a global preclinical and clinical CRO with full GLP toxicology, PK/PD, and bioanalytical capabilities. It competes with Biomere across early-stage in vivo studies and offers the larger, integrated alternative that sponsors often consolidate toward.

Regional players

  • Shanghai Medicilon: Medicilon is a China-based preclinical CRO offering in vivo PK/PD, toxicology, and bioanalytical services with a US presence. It is comparable to Biomere in preclinical service scope, particularly for sponsors seeking China-based execution and IND-enabling support.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Biomere social profiles

Digital presence

Biomere compliance and trust

Trust signal

Compliance10 records

Biomere financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biomere leadership team

Management profile

Number of profiles

Profiles3 records

Biomere funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biomere M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biomere

What does Biomere do?

Biomere is a Boston-area preclinical contract research organization (CRO) that delivers non-GLP pharmacokinetic/pharmacodynamic (PK/PD) and early toxicology studies in rodent, large animal, and non-human primate models. The company operates extensive AAALAC-accredited vivarium space and integrated laboratory sciences (flow cytometry, MSD multiplex assays, qPCR, clinical chemistry) to generate endpoint data packages that support go/no-go decisions and the transition from lead optimization to IND-enabling studies.

Is Biomere a public or private company?

Biomere is a private company. It is classified as corporate owned and is currently operating.

When was Biomere founded?

Biomere was founded in 1996. It employs 101 to 250 people.

Where is Biomere based?

Biomere is headquartered in Worcester, United States, in the North America region.

How does Biomere make money?

One revenue line is on record: preclinical Contract Research Services.

Who are Biomere's main competitors?

Emulate Inc. is listed as an emerging player. Direct peers are Inotiv, JOINN Laboratories, Pharmaron and Frontage Laboratories. Broad incumbents are Eurofins Scientific, WuXi AppTec, Charles River Laboratories and Labcorp (Covance). Shanghai Medicilon is listed as a regional player.

Does Biomere have an API?

No public API is recorded for Biomere.

What industry is Biomere in?

Biomere's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAC, Toxicology & Safety Assessment CROs (GLP). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals